Search research articles
Contact Us
Filters
Showing results (91-100 of 155) with videos related to
Page
of 16
Sort By:
Blood
|
June 27, 2012
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Haematologica
|
July 3, 2025
Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial
Alexey V Danilov, Hongli Li, Mazyar Shadman, et al.
The Canadian Journal of Hospital Pharmacy
|
February 13, 2025
Health Care Workers' Perceptions of a Pharmacist-Led Collaborative Practice Agreement for Prescribing Nirmatrelvir/Ritonavir to Eligible Patients with COVID-19
Britney Sansom, Bradley B Adams, Donaldo D Canales, et al.
Leukemia & Lymphoma
|
April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Transplantation
|
July 23, 2008
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder
Lode J Swinnen, Michael LeBlanc, Thomas M Grogan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2004
Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial
Susan G Urba, James Moon, P G Shankar Giri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2008
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014
Daniel O Persky, Joseph M Unger, Catherine M Spier, et al.
Blood
|
May 10, 2003
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
Oliver W Press, Joseph M Unger, Rita M Braziel, et al.
JCO Oncology Practice
|
July 30, 2025
Development of Ambulatory Oncology Clinical Pharmacy Key Performance Indicators Using a Modified Delphi Consensus Approach
Thomas McFarlane, Rozhannaa Sothilingam, Olavo Fernandes, et al.
Scientific Reports
|
November 24, 2015
Experiments and Model for Serration Statistics in Low-Entropy, Medium-Entropy, and High-Entropy Alloys
Robert Carroll, Chi Lee, Che-Wei Tsai, et al.
Page
of 16
Search research articles
Search
Showing results (91-100 of 155) with videos related to
Sort By:
Page
of 16
Blood
|
June 27, 2012
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Haematologica
|
July 3, 2025
Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial
Alexey V Danilov, Hongli Li, Mazyar Shadman, et al.
The Canadian Journal of Hospital Pharmacy
|
February 13, 2025
Health Care Workers' Perceptions of a Pharmacist-Led Collaborative Practice Agreement for Prescribing Nirmatrelvir/Ritonavir to Eligible Patients with COVID-19
Britney Sansom, Bradley B Adams, Donaldo D Canales, et al.
Leukemia & Lymphoma
|
April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Transplantation
|
July 23, 2008
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder
Lode J Swinnen, Michael LeBlanc, Thomas M Grogan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2004
Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial
Susan G Urba, James Moon, P G Shankar Giri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2008
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014
Daniel O Persky, Joseph M Unger, Catherine M Spier, et al.
Blood
|
May 10, 2003
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
Oliver W Press, Joseph M Unger, Rita M Braziel, et al.
JCO Oncology Practice
|
July 30, 2025
Development of Ambulatory Oncology Clinical Pharmacy Key Performance Indicators Using a Modified Delphi Consensus Approach
Thomas McFarlane, Rozhannaa Sothilingam, Olavo Fernandes, et al.
Scientific Reports
|
November 24, 2015
Experiments and Model for Serration Statistics in Low-Entropy, Medium-Entropy, and High-Entropy Alloys
Robert Carroll, Chi Lee, Che-Wei Tsai, et al.
Page
of 16